Allele Discriminating Priming System,
The most precise cancer mutation diagnostic platform technology
Analyze 1st stage cancer patient’s ctDNA using liquid biopsy
Optimized for precision medicine and companion diagnostics
Based on qPCR, easy and quick
In order to improve detection sensitivity with no false positive, we succeeded in the bold challenge of adding ability to discriminate mutations to DNA polymerase which directly involved in gene amplification. Based on this, we developed ADPS™, a cancer molecular diagnostic platform. ADPS™, capable of both tissue and liquid biopsy, supports more efficient precision medicine with a maximum detection sensitivity of 0.0001%.
ADPS™ is a qPCR-based cancer diagnosis technology that precisely analyzes cancer genes with a detection sensitivity of up to 0.0001% (3/3,000,000).
The new ADPS™ Smart DNA Polymerase can distinguish between normal and mutant genes and amplifies only the mutant genes.
ADPS™ achieved detection sensitivity of 0.01% without false positive by amplifying mutated DNAs only while leaving the wild intact.
A detection sensitivity of 0.01% to 1% is required to analyze ctDNA from the patients, but current liquid biopsy diagnostic technology fails to attain a detection sensitivity of 0.01%.
ADPS™ can be used in full cycle of cancer treatment, from prognosis, diagnosis, and prediction, to treatment decision assistance, treatment monitoring, and relapse testing.
This page provides recently completed clinical trials results Check out the performance of ADPS™ and learn more about us.